Plain-English translation of NCT07072910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether cabergoline, a medication that works on dopamine in the brain, can help prevent migraines from happening as often. A small earlier study showed promising results, and this larger trial wants to confirm whether the medication works and find the best dose. You'll track your migraines carefully throughout the study to see if the treatment makes a real difference in your life.
Many people with migraines still have frequent attacks despite current treatments, and some struggle with side effects or can't access newer therapies. This medication might offer another option for people whose migraines aren't well controlled.
You likely qualify if…
You likely don't qualify if…
For the first 12 weeks, you'll take a weekly pill (either the medication at one of two doses or a placebo — you won't know which) and report your migraines in a secure online diary. Then for another 12 weeks, everyone receives the actual medication in an open-label phase. You'll answer questions about your headaches, disability, and work, give blood samples to help researchers understand how the medication works, and have a final safety check-in four weeks after you stop treatment.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Denmark